Cagrilintide: difference between revisions
Diff·revision 18 → 19·12:34, 21 Jun 2025
Difference between revision 18 and revision 19 of Cagrilintide. 7 lines changed; the page grew by 839 bytes.
| Revision 18 — 04:09, 25 May 2025 CiteBot (talk) bot: expand DOI to full citation 3,213 bytes ±0 | Revision 19 — 12:34, 21 Jun 2025 LiraLotte (talk) add CAS number, sourced 4,052 bytes +839 | ||
|---|---|---|---|
| 29 | No cardiovascular or other outcome evidence exists for this compound.{{r|lau2021}} | 29 | No cardiovascular or other outcome evidence exists for this compound.{{r|lau2021}} |
| 30 | 30 | ||
| + | 31 | == Material sold under the name == | |
| + | 32 | Cagrilintide is offered by research-chemical suppliers. It is an unapproved investigational compound and this wiki does not represent it as suitable for human use; see [[Research use only]].{{r|reports}} | |
| + | 33 | ||
| + | 34 | Analytically it presents the difficulty common to amylin analogues: residual aggregation propensity means that size-based methods carry weight a [[Reverse-phase HPLC|reverse-phase]] purity determination cannot supply, since aggregates dissociate under reverse-phase conditions. See [[Peptide aggregation]].{{r|usp1503}} | |
| + | 35 | ||
| 31 | == References == | 36 | == References == |
| 32 | {{reflist}} | 37 | {{reflist}} |
| 33 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> | 38 | <ref name="lau2021">Lau DCW, Erichsen L, Francisco AM, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." ''The Lancet'' 398(10317):2160–2172 (2021). PMID 34798060.</ref> |
| 34 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> | 39 | <ref name="hay2015">Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. "Amylin: pharmacology, physiology, and clinical potential." ''Pharmacological Reviews'' 67(3):564–600 (2015). PMID 26071095.</ref> |
| + | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| + | 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | |
| 35 | 42 | ||
| 36 | == See also == | 43 | == See also == |